No Carolina / NY / Florida
Ph: 561.316.3330

spot_img

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

The new Roden ADA Kit expedites bioanalysis by removing the need for assay development and optimization across molecules to provide robust, reproducible, reliable data from nanoliter sample volumes. This is beneficial when ADA assessment is evaluated in preclinical animal models where sample volume may be limited.

Newly Published Society of Interventional Radiology Position Statement Outlines Appropriate Use of Endovascular Management for Treatment of Chronic Iliofemoral Venous Occlusions

Summation

  • “There is strong consensus on the panel that excellent clinical decision-making around venous stent placement will be most likely when the treating physician has strong familiarity with key clinical considerations around optimal diagnosis and evaluation of iliac vein obstruction, as well as assessment of its clinical severity and life impact,” said Suresh Vedantham, MD, FSIR, the lead author and an interventional radiologist and professor with the Washington University in St.
  • In the new statement, the multidisciplinary group of experts from interventional radiology, vascular medicine, and vascular surgery indicated that among patients with chronic venous disease and iliofemoral venous obstruction, those who are experiencing life disrupting symptoms or disability and who have anatomic features that favor long-term patency may be more likely to benefit from stenting as an adjunct to conservative management.
  • “The new statement provides the best assessment of the current evidence we have to date, and SIR is grateful to the authors for their time and energy in ensuring that we have evidence-based guidance for the treatment of chronic venous occlusions,” said SIR President Alda L.

The Society of Interventional Radiology published a new position statement offering recommendations on the management of chronic iliofemoral venous obstruction with endovascular placement of metallic stents. The statement, published online in the Journal of Vascular and Interventional Radiology, is a companion to the 2022 statement on the treatment of acute iliofemoral deep vein thrombosis.

In the new statement, the multidisciplinary group of experts from interventional radiology, vascular medicine, and vascular surgery indicated that among patients with chronic venous disease and iliofemoral venous obstruction, those who are experiencing life disrupting symptoms or disability and who have anatomic features that favor long-term patency may be more likely to benefit from stenting as an adjunct to conservative management. Most other patients with chronic iliofemoral venous occlusions would be better served with conservative management alone, such as use of medical therapy and compression garments, and re-evaluated over time.

“There is strong consensus on the panel that excellent clinical decision-making around venous stent placement will be most likely when the treating physician has strong familiarity with key clinical considerations around optimal diagnosis and evaluation of iliac vein obstruction, as well as assessment of its clinical severity and life impact,” said Suresh Vedantham, MD, FSIR, the lead author and an interventional radiologist and professor with the Washington University in St. Louis. “The statement provides a framework against which IR physicians can review their practices, address knowledge gaps, deliver treatment effectively, and ensure that patients selected for stent placement are likely to benefit from it.”

The statement authors note that additional research is needed to better guide the use of stents in this patient population. If completed, two ongoing multicenter randomized controlled trials—C-TRACT and BEST—can enable a strong and unbiased understanding of the treatment effects associated with the addition of venous stent placement to standard care, Vedantham said.

“For both studies, success will depend on whether providers make it a priority to refer patients to study sites,” he said. “It is hoped that physicians will promote the welfare of future venous disease patients by actively choosing now to enroll eligible patients in ongoing clinical trials that are designed to generate high-quality evidence on the benefits, risks, and best practices around venous stent placement.”

While this research proceeds, SIR believes that adherence to the statement’s recommendations will enable judicious use of endovascular therapy in a manner that optimizes benefit and minimizes harm.

“The new statement provides the best assessment of the current evidence we have to date, and SIR is grateful to the authors for their time and energy in ensuring that we have evidence-based guidance for the treatment of chronic venous occlusions,” said SIR President Alda L. Tam, MD, MBA, FSIR, an interventional radiologist and professor at the University of Texas MD Anderson Cancer Center in Houston. “SIR remains committed to supporting ongoing and future research in this area to ensure that physicians have the information they need to optimize patient care now and in the future.”

SonoVascular Enters Into Strategic Collaboration with Lantheus Holdings | for Use of Microbubbles in Combination with SonoThrombectomy™ System for Treatment of Venous Thromboembolism

"SonoVascular is honored to have the opportunity to partner with Lantheus, a leader in microbubble development," said Daniel Estay, Founder and Chief Executive Officer of SonoVascular. "Our SonoThrombectomy System, combined with Lantheus' microbubbles, is designed to provide a true, next-generation solution for the treatment of DVT and PE that overcomes the drawbacks associated with catheter-based thrombectomy and thrombolysis devices."

Anaut Announces Japanese Regulatory Approval of AI-Powered Surgical Visualization Tool, Eureka α

Eureka α utilizes state-of-the-art AI to analyze real-time video from laparoscopic and robotic surgery, enhancing surgeons' accuracy by highlighting the dissection planes characterized by connective tissue.

Discover Reeva FT: Revolutionizing Wound Covering for Healthcare Pros

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

By using this website you agree to accept Medical Device News Magazine Privacy Policy